Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model

International Journal of Antimicrobial Agents

Volumn 36, Issue 1, 2010, Pages 33-36

  Krishnan Natesan, Suganthini ^a,b   Manavathu, Elias K ^a   Cutright, Jessica L ^a   Chandrasekar, Pranatharthi H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anidulafungin; Candida albicans; Candidiasis; Drug efficacy; Echinocandins; Murine model; Rapid killing

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; IMMUNOCOMPROMISED PATIENT; IN VIVO STUDY; INVASIVE CANDIDIASIS; KIDNEY PARENCHYMA; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY; MICE; MICE, INBRED ICR; NEUTROPENIA; SPLEEN; TREATMENT OUTCOME;

EID: 77953020219     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.02.020     Document Type: Article

References (31)

1. Glöckner A., Steinbach A., Vehreschild J.J., Cornely O.A. Treatment of invasive candidiasis with echinocandins. Mycoses 2009, 52:476-486.
2. Sobel J.D., Revankar S.G. Echinocandins-first-choice or first-line therapy for invasive candidiasis?. N Engl J Med 2007, 356:2525-2526.
3. Turner M.S., Drew R.H., Perfect J.R. Emerging echinocandins for treatment of invasive fungal infections. Expert Opin Emerg Drugs 2006, 11:231-235.
4. Kim R., Khachikian D., Reboli A.C. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin Pharmacother 2007, 8:1479-1492.
5. Cornely O.A., Schmitz K., Aisenbrey S. The first echinocandin: caspofungin. Mycoses 2002, 45(Suppl. 3):56-60.
6. Cornely O.A., Lasso M., Betts R., Klimko N., Vazquez J., Dobb G., et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007, 60:363-369.
7. Betts R., Glasmacher A., Maertens J., Maschmeyer G., Vazquez J.A., Teppler H., et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006, 106:466-473.
8. Lichtenstern C.T., Nguyen H., Schemmer P., Hoppe-Tichy T., Weigand M.A. Efficacy of caspofungin in invasive candidiasis and candidemia-de-escalation strategy. Mycoses 2008, 51(Suppl. 1):35-46.
9. Ellis M., Frampton C., Joseph J., Alizadeh H., Kristensen J., Hauggaard A., et al. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy. J Med Microbiol 2006, 55:1357-1365.
10. Cross S.A., Scott L.J. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections. Drugs 2008, 68:2225-2255.
11. Estes K.E., Penzak S.R., Calis K.A., Walsh T.J. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy 2009, 29:17-30.
12. Nir-Paz R., Moses A.A. Anidulafungin and fluconazole for candidiasis. N Engl J Med 2007, 357:1347-1348.
13. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482.
14. Onishi J., Meinz M., Thompson J., Curotto J., Dreikorn S., Rosenbach M., et al. Discovery of novel antifungal (1,3)-β-d-glucan synthase inhibitors. Antimicrob Agents Chemother 2000, 44:368-377.
15. Douglas C.M., D'Ippolito J.A., Shei G.J., Meinz M., Onishi J., Marrinan J.A., et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-d-glucan synthase inhibitors. Antimicrob Agents Chemother 1997, 41:2471-2479.
16. Radding J.A., Heidler S.A., Turner W.W. Photoaffinity analog of the semisynthetic echinocandin LY303366: identification of echinocandin targets in Candida albicans. Antimicrob Agents Chemother 1998, 42:1187-1194.
17. Pappas P.G., Rotstein C.M., Betts R.F., Nucci M., Talwar D., De Waele J.J., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.
18. Arevalo M.P., Carrillo-Munoz A.J., Salgado J., Cardenes D., Brio S., Quindos G., et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother 2003, 51:163-166.
19. Dannaoui E., Lortholary O., Raoux D., Bougnoux M.E., Galeazzi G., Lawrence C., et al. Comparative in vitro activity of caspofungin and micafungin, using the method of the European Committee on Antimicrobial Susceptibility Testing (EUCAST), against yeast isolates from France (2005-2006). Antimicrob Agents Chemother 2008, 52:778-781.
20. Pfaller M.A., Diekema D.J., Ostrosky-Zeichner L., Rex J.H., Alexander B.D., Andes D., et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008, 46:2620-2629.
21. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008, 46:150-156.
22. Pfaller M.A., Boyken L., Hollis R.J., Messer S.A., Tendolkar S., Diekema D.J., et al. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006, 44:760-763.
23. Pfaller M.A., Chaturvedi V., Diekema D.J., Ghannoum M.A., Holliday N.M., Killian S.B., et al. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J Clin Microbiol 2008, 46:2155-2159.
24. Pfaller M.A., Boyken L., Hollis R.J., Messer S.A., Tendolkar S., Diekema D.J. In vitro activities of anidulafungin against more than 2500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005, 43:5425-5427.
25. Gumbo T. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies. Curr Opin Infect Dis 2007, 20:587-591.
26. Andes D., Diekema D.J., Pfaller M.A., Prince R.A., Marchillo K., Ashbeck J., et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008, 52:539-550.
27. Gumbo T., Drusano G.L., Liu W., Ma L., Deziel M.R., Drusano M.F., et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006, 50:3695-3700.
28. Hajdu R., Thompson R., Sundelof J.G., Pelak B.A., Bouffard F.A., Dropinski J.F., et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997, 41:2339-2344.
29. Sandhu P., Xu X., Bondiskey P.J., Balani S.K., Morris M.L., Tang Y.S., et al. Disposition of caspofungin, a novel antifungal agent in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother 2004, 48:1272-1280.
30. Stone J.A., Holland S.D., Wicjersham P.J., Sterrett A., Schwartz M., Bonfiglio C., et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002, 46:739-745.
31. Damle B., Stogniew M., Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother 2008, 52:2673-2676.